Investigational drug · Phase 2
RO6874281
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Pancreatic Adenocarcinoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 21, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
5
Any phase or sponsor naming "RO6874281"
First trial start
2017
Jul 5, 2017
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "RO6874281", any sponsor or status.
Conditions studied
As listed on its trial records.
- Pancreatic Adenocarcinoma
Approved drugs for the same conditions: Pancreatic cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "RO6874281" as an intervention, largest first.
- A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)Pivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03193190 · 341 participants · Start Jul 5, 2017 · Primary completion Feb 27, 2025
Drug: Nab-Paclitaxel; Gemcitabine and 13 more · For: Pancreatic Adenocarcinoma
Sites: Duarte, California; San Francisco, California; New Haven, Connecticut · 23 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03386721 · 256 participants · Start Feb 19, 2018 · Primary completion Dec 30, 2021
Drug: simlukafusp alfa; Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody and 2 more · For: Advanced/Metastatic Head and Neck, Oesophageal and Cervical Cancers
Sites: San Francisco, California; Newnan, Georgia; Edegem, Belgium · 44 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT02627274 · 134 participants · Start Dec 7, 2015 · Primary completion Nov 10, 2022
Drug: RO6874281; Trastuzumab and 1 more · For: Solid Tumor; Breast Cancer; Cancer of Head and Neck
Sites: Tucson, Arizona; La Jolla, California; Greeley, Colorado · 26 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03875079 · 83 participants · Start Jun 24, 2019 · Primary completion Jul 14, 2022
Drug: RO6874281; Pembrolizumab · For: Metastatic Melanoma
Sites: New Haven, Connecticut; Iowa City, Iowa; Boston, Massachusetts · 23 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03063762 · 69 participants · Start Mar 20, 2017 · Primary completion Jun 14, 2021
Drug: Atezolizumab; Bevacizumab and 1 more · For: Renal Cell Carcinoma
Sites: New Haven, Connecticut; Chicago, Illinois; Baltimore, Maryland · 23 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma.
Munoz-Couselo E, Soria Rivas A, Sandhu S, et al. · Cancer Res Commun 2025
- Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy.
Waldhauer I, Gonzalez-Nicolini V, Freimoser-Grundschober A, et al. · MAbs 2021
Also in development for Pancreatic Adenocarcinoma
- TiragolumabMTIG7192A, RO7092284Phase 311 trials
Roche (Genentech) · Hepatocellular Carcinoma, Rectal Neoplasms, Rectal Cancer
- GEMPhase 35 trials
Shenzhen Majory Biotechnology Co., Ltd. · Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Cancer, Recurrent or Metastatic Cervical Cancer
- AtebimetinibIMM-1-104, Group APhase 34 trials
Immuneering Corporation · Pancreatic Adenocarcinoma, Advanced Solid Tumor, Malignant Melanoma (Cutaneous)
- zoldonrasibPhase 34 trials
Revolution Medicines, Inc. · Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC
- BL-8040Phase 32 trials
BioLineRx, Ltd. · Multiple Myeloma, Pancreatic Adenocarcinoma
- CF102NamodenosonPhase 32 trials
Can-Fite BioPharma · Pancreatic Adenocarcinoma, Pancreatic Cancer, Hepatocellular Carcinoma
- AB928Etrumadenant, ETRUMAPhase 24 trials
Arcus Biosciences, Inc. · Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer
- ImzokitugBMS-986340Phase 22 trials
Bristol Myers Squibb · Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC), Cervical Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Roche (Genentech).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.